Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation

Authors: Chat, Vipawee S., Ellebrecht, Christoph T., Kingston, Paige, Gondo, George, Bell, Stacie, Cordoro, Kelly M., Desai, Seemal R., Duffin, Kristina C., Feldman, Steven R., Garg, Amit, Gelfand, Joel M., Gladman, Dafna, Green, Lawrence J., Gudjonsson, Johann, Han, George, Hawkes, Jason E., Kircik, Leon, Koo, John, Langley, Richard, Lebwohl, Mark, Michael Lewitt, G., Liao, Wilson, Martin, George, Orbai, Ana-Maria, Reddy, Soumya M., Richardson, Veronica, Ritchlin, Christopher T., Schwartzman, Sergio, Siegel, Evan L., Van Voorhees, Abby S., Wallace, Elizabeth B., Weinberg, Jeffrey M., Winthrop, Kevin L., Yamauchi, Paul, Armstrong, April W.

Source: In Journal of the American Academy of Dermatology June 2024 90(6):1170-1181

IL-23 induces CLEC5A+ IL-17A+ neutrophils and elicit skin inflammation associated with psoriatic arthritis

Authors: Furuya, Hiroki, Nguyen, Cuong Thach, Chan, Trevor, Marusina, Alina I., Merleev, Alexander A., Garcia-Hernandez, Maria de la Luz, Hsieh, Shie-Liang, Tsokos, George C., Ritchlin, Christopher T., Tagkopoulos, Ilias, Maverakis, Emanual, Adamopoulos, Iannis E.

Source: In Journal of Autoimmunity February 2024 143

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Authors: Merola, Joseph F, Landewé, Robert, McInnes, Iain B ^*, Mease, Philip J, Ritchlin, Christopher T, Tanaka, Yoshiya, Asahina, Akihiko, Behrens, Frank, Gladman, Dafna D, Gossec, Laure, Gottlieb, Alice B, Thaçi, Diamant, Warren, Richard B, Ink, Barbara, Assudani, Deepak, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, Coates, Laura C

Source: In The Lancet 7-13 January 2023 401(10370):38-48

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

Authors: McInnes, Iain B ^*, Asahina, Akihiko, Coates, Laura C, Landewé, Robert, Merola, Joseph F, Ritchlin, Christopher T, Tanaka, Yoshiya, Gossec, Laure, Gottlieb, Alice B, Warren, Richard B, Ink, Barbara, Assudani, Deepak, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, Mease, Philip J

Source: In The Lancet 7-13 January 2023 401(10370):25-37

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments

Authors: Gelfand, Joel M., Armstrong, April W., Bell, Stacie, Anesi, George L., Blauvelt, Andrew, Calabrese, Cassandra, Dommasch, Erica D., Feldman, Steven R., Gladman, Dafna, Kircik, Leon, Lebwohl, Mark, Lo Re, Vincent, III, Martin, George, Merola, Joseph F., Scher, Jose U., Schwartzman, Sergio, Treat, James R., Van Voorhees, Abby S., Ellebrecht, Christoph T., Fenner, Justine, Ocon, Anthony, Syed, Maha N., Weinstein, Erica J., Gondo, George, Heydon, Sue, Koons, Samantha, Ritchlin, Christopher T.

Source: In Journal of the American Academy of Dermatology May 2021 84(5):1254-1268

Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials.

Authors: Norton, Hillary, Sliwinska-Stanczyk, Paula, Hala, Tomas, El-Zorkany, Bassel, Stockert, Lori, Mundayat, Rajiv, Wang, Lisy, Ritchlin, Christopher T.

Source: Rheumatology & Therapy; Feb2025, Vol. 12 Issue 1, p67-84, 18p

Subject Terms: ANKYLOSING spondylitis, BODY mass index, TUMOR necrosis factors, JOINT diseases, C-reactive protein

Are There Disease Endotypes in Axial Spondyloarthritis and How Would We Define Them?

Authors: Deane, Kevin D.¹, Donlin, Laura T.², Ritchlin, Christopher T.³, Kuhn, Kristine A.¹ kristine.kuhn@cuanschutz.edu

Source: Journal of Rheumatology. Dec2024, Vol. 51 Issue 12, p1229-1234. 6p.

National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1

Authors: Gelfand, Joel M., Armstrong, April W., Bell, Stacie, Anesi, George L., Blauvelt, Andrew, Calabrese, Cassandra, Dommasch, Erica D., Feldman, Steve R., Gladman, Dafna, Kircik, Leon, Lebwohl, Mark, Lo Re, Vincent, III, Martin, George, Merola, Joseph F., Scher, Jose U., Schwartzman, Sergio, Treat, James R., Van Voorhees, Abby S., Ellebrecht, Christoph T., Fenner, Justine, Ocon, Anthony, Syed, Maha N., Weinstein, Erica J., Smith, Jessica, Gondo, George, Heydon, Sue, Koons, Samantha, Ritchlin, Christopher T.

Source: In Journal of the American Academy of Dermatology December 2020 83(6):1704-1716

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

Authors: Deodhar, Atul ^*, Helliwell, Philip S, Boehncke, Wolf-Henning, Kollmeier, Alexa P, Hsia, Elizabeth C, Subramanian, Ramanand A, Xu, Xie L, Sheng, Shihong, Agarwal, Prasheen, Zhou, Bei, Zhuang, Yanli, Ritchlin, Christopher T

Source: In The Lancet 4-10 April 2020 395(10230):1115-1125

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

Authors: Ritchlin, Christopher T ^*, Kavanaugh, Arthur, Merola, Joseph F, Schett, Georg, Scher, Jose U, Warren, Richard B, Gottlieb, Alice B, Assudani, Deepak, Bedford-Rice, Kathy, Coarse, Jason, Ink, Barbara, McInnes, Iain B

Source: In The Lancet 8-14 February 2020 395(10222):427-440

63 - Anti-cytokine Biologics

Authors: Ritchlin, Christopher T., Kavanaugh, Arthur, Mccarthy, Katharine

Source: In Firestein & Kelley’s Textbook of Rheumatology, 2-Volume Set Edition: Twelfth Edition. 2025:1041-1064

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.

Authors: Mease, Philip J., Merola, Joseph F., Tanaka, Yoshiya, Gossec, Laure, McInnes, Iain B., Ritchlin, Christopher T., Landewé, Robert B. M., Asahina, Akihiko, Ink, Barbara, Heinrichs, Andrea, Bajracharya, Rajan, Shende, Vishvesh, Coarse, Jason, Coates, Laura C.

Source: Rheumatology & Therapy; Oct2024, Vol. 11 Issue 5, p1363-1382, 20p

Subject Terms: TUMOR necrosis factors, ANTIRHEUMATIC agents, PSORIATIC arthritis, TREATMENT effectiveness, ADALIMUMAB, CHRONIC diseases

The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial.

Authors: Ritchlin, Christopher T.¹ (AUTHOR) christopher_ritchlin@urmc.rochester.edu, Coates, Laura C.² (AUTHOR), Mease, Philip J.³ (AUTHOR), van der Heijde, Désirée⁴ (AUTHOR), Song, Jiao⁵ (AUTHOR), Jiang, Yusang⁶ (AUTHOR), Shawi, May⁷ (AUTHOR), Kollmeier, Alexa P.⁵ (AUTHOR), Rahman, Proton⁸ (AUTHOR)

Source: Trials. 1/10/2023, Vol. 24 Issue 1, p1-12. 12p. 1 Diagram, 4 Charts.

Subject Terms: *PSORIATIC arthritis, *ANTIRHEUMATIC agents, *CLINICAL trials, *RESEARCH protocols, *ANALYSIS of covariance, *C-reactive protein

Chronic social stress Ameliorates psoriasiform dermatitis through upregulation of the Hypothalamic-Pituitary-Adrenal axis

Authors: Vegas, Oscar, Poligone, Brian, Blackcloud, Paul, Gilmore, Elaine S., VanBuskirk, JoAnne, Ritchlin, Christopher T., Pentland, Alice P., Walter, Scott A., Nousari, Yasmine, Tausk, Francisco

Source: In Brain Behavior and Immunity February 2018 68:238-247

Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.

Authors: Ritchlin, Christopher T.¹ (AUTHOR) christopher_ritchlin@URMC.Rochester.edu, Mease, Philip J.^2,3 (AUTHOR), Boehncke, Wolf-Henning⁴ (AUTHOR), Tesser, John⁵ (AUTHOR), Chakravarty, Soumya D.^6,7 (AUTHOR), Rampakakis, Emmanouil^8,9 (AUTHOR), Shawi, May¹⁰ (AUTHOR), Schiopu, Elena¹¹ (AUTHOR), Merola, Joseph F.¹² (AUTHOR), McInnes, Iain B.¹³ (AUTHOR), Deodhar, Atul¹⁴ (AUTHOR)

Source: Clinical Rheumatology. Aug2024, Vol. 43 Issue 8, p2551-2563. 13p.

Subject Terms: *PSORIATIC arthritis, *BODY mass index, *PATIENT reported outcome measures, *C-reactive protein, *JOINT diseases

High-throughput micro-CT analysis identifies sex-dependent biomarkers of erosive arthritis in TNF-Tg mice and differential response to anti-TNF therapy.

Authors: Kenney, H. Mark, Chen, Kiana L., Schnur, Lindsay, Fox, Jeffrey I., Wood, Ronald W., Xing, Lianping, Ritchlin, Christopher T., Rahimi, Homaira, Schwarz, Edward M., Awad, Hani A.

Source: PLoS ONE; 7/5/2024, Vol. 19 Issue 7, p1-26, 26p

Subject Terms: ANKLE, X-ray computed microtomography, ANKLEBONE, ANKLE joint, TUMOR necrosis factors, BIOMARKERS, TREATMENT effectiveness, BONE regeneration

MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis

Authors: Yoo, Seung-Ah, Leng, Lin, Kim, Bum-Joon, Du, Xin, Tilstam, Pathricia V., Kim, Kyung Hee, Kong, Jin-Sun, Yoon, Hyung-Ju, Liu, Aihua, Wang, Tian, Song, Yan, Sauler, Maor, Bernhagen, Jurgen, Ritchlin, Christopher T., Lee, Patty, Cho, Chul-Soo, Kim, Wan-Uk, Bucala, Richard

Source: Proceedings of the National Academy of Sciences of the United States of America, 2016 Dec 01. 113(49), E7917-E7926.

Access URL: https://www.jstor.org/stable/26472792

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study

Authors: Ogdie, Alexis, Merola, Joseph F., Mease, Philip J., Ritchlin, Christopher T., Scher, Jose U., Lafferty, Kimberly Parnell, Chan, Daphne, Chakravarty, Soumya D., Langholff, Wayne, Wang, Yanli, Choi, Olivia, Krol, Yevgeniy, Gottlieb, Alice B.

Source: BMC Rheumatology; 5/21/2024, Vol. 8 Issue 1, p1-12, 12p

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy.

Authors: Krueger, James G., Eyerich, Kilian, Kuchroo, Vijay K., Ritchlin, Christopher T., Abreu, Maria T., Elloso, M. Merle, Fourie, Anne, Fakharzadeh, Steven, Sherlock, Jonathan P., Ya-Wen Yang, Cua, Daniel J., McInnes, Iain B.

Source: Frontiers in Immunology; 2024, p1-15, 15p

Subject Terms: INFLAMMATORY bowel diseases, PSORIATIC arthritis

Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture

Authors: Stuart, Philip E., Nair, Rajan P., Tsoi, Lam C., Tejasvi, Trilokraj, Das, Sayantan, Kang, Hyun Min, Ellinghaus, Eva, Chandran, Vinod, Callis-Duffin, Kristina, Ike, Robert, Li, Yanming, Wen, Xiaoquan, Enerbäck, Charlotta, Gudjonsson, Johann E., Kõks, Sulev, Kingo, Külli, Esko, Tõnu, Mrowietz, Ulrich, Reis, Andre, Wichmann, H. Erich, Gieger, Christian, Hoffmann, Per, Nöthen, Markus M., Winkelmann, Juliane, Kunz, Manfred, Moreta, Elvia G., Mease, Philip J., Ritchlin, Christopher T., Bowcock, Anne M., Krueger, Gerald G., Lim, Henry W., Weidinger, Stephan, Weichenthal, Michael, Voorhees, John J., Rahman, Proton, Gregersen, Peter K., Franke, Andre, Gladman, Dafna D., Abecasis, Gonçalo R., Elder, James T.

Source: In The American Journal of Human Genetics 3 December 2015 97(6):816-836